1007208-67-4

Upstream product

• 1007215-39-5 6-chloro-5-(2-chloroethyl)-N-[(4-methoxyphenyl)methyl]-2-morpholinopyrimidin-4-amine 
• 1007215-41-9 4-[4-chloro-7-[(4-methoxyphenyl)methyl]-5,6-dihydropyrrolo[2,3-d]pyrimidin-2-yl]morpholine 
• 1007215-43-1 4-(4-chloro-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine 
• 1178564-19-6 1-[4-[2-[bis[(4-methoxyphenyl)methyl]amino]pyrimidin-5-yl]-2-morpholino-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-7-yl]ethanone 
• 1178564-17-4 5-(2-hydroxyethyl)-2-morpholin-4-yl-pyrimidine-4,6-diol 
• 5638-78-8 morpholinoformamidine hydrochloride 
• 1007207-65-9 N,N-bis[(4-methoxyphenyl)methyl]-5-(2-morpholino-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine 
• 1007213-39-9 1-(4-chloro-2-morpholino-5,6-dihydropyrrolo[2,3-d]pyrimidin-7-yl)ethanone 
• 127915-15-5 2-oxotetrahydrofuran-3-carboxylic acid methyl ester 
• 1007206-27-0 4-[4,6-dichloro-5-(2-chloroethyl)-pyrimidin-2-yl]-morpholine 

Relevant academic research and scientific papers

Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability

Phosphoinositide 3-kinase (PI3K) is activated in various human cancer cells and well known as a cancer therapy target. We previously reported a dihydropyrrolopyrimidine derivative as a highly potent PI3K inhibitor that has strong tumor growth inhibition in a xenograft model. In this report, we describe further optimization to improve its bioavailability.

PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF

A drug is provided that is useful as a preventive or therapeutic for cancer as a result of having superior PI3K inhibitory effects as well as superior stability in the body and water-solubility. A compound, or pharmaceutically acceptable salt thereof, rep